Blood test could predict vasculitis relapse, study hopes
NCT ID NCT07636655
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 120 adults with ANCA-associated vasculitis, an autoimmune disease, who are receiving rituximab therapy. Researchers will collect blood samples over time to look for immune cell changes that signal a coming relapse. The goal is to find biomarkers that help doctors tailor treatment duration and reduce unnecessary side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab (a drug that depletes B-cells)
What this could lead to
If successful, this could lead to a blood test that helps doctors predict when a patient with vasculitis might relapse, allowing for shorter, safer treatment.
What could go wrong
This is an observational study, not a treatment trial. It may not find reliable markers, and any findings will need further validation before changing patient care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nantes
Nantes, Loire-atlantique, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••